WO2002027027A8 - Criblage de substances therapeutiques en rapport avec des maladies infectieuses - Google Patents

Criblage de substances therapeutiques en rapport avec des maladies infectieuses

Info

Publication number
WO2002027027A8
WO2002027027A8 PCT/US2001/030334 US0130334W WO0227027A8 WO 2002027027 A8 WO2002027027 A8 WO 2002027027A8 US 0130334 W US0130334 W US 0130334W WO 0227027 A8 WO0227027 A8 WO 0227027A8
Authority
WO
WIPO (PCT)
Prior art keywords
screening
therapeutics
infectious diseases
gene products
differentially expressed
Prior art date
Application number
PCT/US2001/030334
Other languages
English (en)
Other versions
WO2002027027A2 (fr
WO2002027027A3 (fr
Inventor
Maurice Zauderer
Original Assignee
Univ Rochester
Maurice Zauderer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester, Maurice Zauderer filed Critical Univ Rochester
Priority to AU2001294831A priority Critical patent/AU2001294831A1/en
Priority to EP01975512A priority patent/EP1335990A2/fr
Priority to CA002423879A priority patent/CA2423879A1/fr
Publication of WO2002027027A2 publication Critical patent/WO2002027027A2/fr
Publication of WO2002027027A3 publication Critical patent/WO2002027027A3/fr
Publication of WO2002027027A8 publication Critical patent/WO2002027027A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention a trait à un méthode de criblage de produits géniques, dérivés de cellules hôtes, se révélant des plus utiles dans le cadre d'une thérapie de maladies infectieuses. La méthode consiste à identifier des gènes exprimés de manière différentielle dans des cellules infectées et à procéder à un criblage de ces produits géniques exprimés aux fins de la détermination de leur pouvoir antigénique.
PCT/US2001/030334 2000-09-29 2001-10-01 Criblage de substances therapeutiques en rapport avec des maladies infectieuses WO2002027027A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001294831A AU2001294831A1 (en) 2000-09-29 2001-10-01 Method of screening for therapeutics for infectious diseases
EP01975512A EP1335990A2 (fr) 2000-09-29 2001-10-01 Criblage de substances therapeutiques en rapport avec des maladies infectieuses
CA002423879A CA2423879A1 (fr) 2000-09-29 2001-10-01 Criblage de substances therapeutiques en rapport avec des maladies infectieuses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23638100P 2000-09-29 2000-09-29
US60/236,381 2000-09-29

Publications (3)

Publication Number Publication Date
WO2002027027A2 WO2002027027A2 (fr) 2002-04-04
WO2002027027A3 WO2002027027A3 (fr) 2003-03-06
WO2002027027A8 true WO2002027027A8 (fr) 2003-10-09

Family

ID=22889250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/030334 WO2002027027A2 (fr) 2000-09-29 2001-10-01 Criblage de substances therapeutiques en rapport avec des maladies infectieuses

Country Status (4)

Country Link
EP (1) EP1335990A2 (fr)
AU (1) AU2001294831A1 (fr)
CA (1) CA2423879A1 (fr)
WO (1) WO2002027027A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135278B1 (en) 2000-09-29 2006-11-14 University Of Rochester Method of screening for therapeutics for infectious diseases
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
CA2576295C (fr) * 2004-08-13 2014-07-29 Athlomics Pty Ltd Diagnostic assiste par micro-puce de l'infection par le virus de l'herpes par monitoring de l'expression du gene differentiel de l'hote lors de l'injection
JP5357782B2 (ja) 2007-02-21 2013-12-04 バクシネックス インコーポレーティッド 抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US6190909B1 (en) * 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
WO2002031117A2 (fr) * 2000-10-13 2002-04-18 Arbor Vita Corporation Proteines transmembranaires clasp-2

Also Published As

Publication number Publication date
WO2002027027A2 (fr) 2002-04-04
CA2423879A1 (fr) 2002-04-04
AU2001294831A1 (en) 2002-04-08
WO2002027027A3 (fr) 2003-03-06
EP1335990A2 (fr) 2003-08-20

Similar Documents

Publication Publication Date Title
WO2003068923A3 (fr) Signal d'incorporation de vecteurs de virus de la grippe
WO2000008196A3 (fr) Urate oxydase
WO2003054197A3 (fr) Bibliotheque de genes structuraux modifies ou de particules modifiees par des capsides utiles pour l'identification de clones viraux par tropisme cellulaire desire
WO2003048348A3 (fr) Production de virus, d'isolats viraux et de vaccins
WO2002046429A3 (fr) Polypeptides possedant une activite glucoamylase et acides nucleiques codant pour
WO2000026349A3 (fr) Oleandolide-polyketide-synthase de recombinaison
AU2002314693A1 (en) Nucleic acid amplification method
WO2000077233A3 (fr) Virus d'adn non mammalien resistant au complement et utilisations de ces virus
AU2001236042A1 (en) Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
EP1474433A4 (fr) VALIDATION ET IDENTIFICATION DE CIBLES FACILITEES PAR INTERFERENCE D'ARN AU MOYEN D'ACIDE NUCLEIQUE INTERFERENT COURT (siNA)
WO2001029222A3 (fr) Polypeptides ayant une activite phospholipase b et acides nucleiques codant ces derniers
WO2002046465A3 (fr) Procede d'analyse
WO2005035556A3 (fr) Particules pseudo-virales du coronavirus du sras et methodes d'utilisation
WO2002006457A3 (fr) Genes de lipase
WO1997005255A3 (fr) Virus auxiliaires pour la preparation de vecteurs viraux recombinants
WO2001057058A3 (fr) Detection d'expression genique differentielle
WO2002038792A3 (fr) Nouvelle methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine (vih)
WO2002027027A3 (fr) Criblage de substances therapeutiques en rapport avec des maladies infectieuses
AU2001247729A1 (en) Sequence-dependent gene sorting techniques
AU2001238616A1 (en) Rapid nucleic acid separation, isolation and purification methods
WO2005108606A3 (fr) Methode d’etude de la variabilite genique et fonctionnelle du vih et kit pour sa mise en oeuvre
WO2005013904A3 (fr) Acides nucleiques, proteines, vaccins contre le sras et leurs utilisations
WO2003049767A3 (fr) Procede de production en serie de virus de l'hepatite a
AU2001250858A1 (en) Methods of preparing amplified nucleic acid molecules
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2423879

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001294831

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001975512

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001975512

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001975512

Country of ref document: EP

WSNC Later publication of a supplementary international search report together with a suppl. search report established by non-competent authority
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase in:

Ref country code: JP